ライフサイエンスコーパス: 18F-FDG

1 18F-FDG has some applicability to localizing a site of i

2 18F-FDG incorporation was significantly increased by 30

3 18F-FDG incorporation, the initial rate of O-methyl-D-gl

4 18F-FDG PET has excellent diagnostic accuracy in Hurthle

5 18F-FDG PET has proved useful in the staging and follow-

6 18F-FDG PET has reached widespread application in the as

7 18F-FDG PET is an early predictor of survival in patient

8 18F-FDG PET is increasingly being used to monitor the ea

9 18F-FDG PET offers the radiation oncology community the

10 18F-FDG PET scans were reviewed and compared with all av

11 18F-FDG PET/CT (visual analysis) detected residual nodal

12 18F-FDG PET/CT allows detection and localization of foci

13 18F-FDG PET/CT findings were correlated with the finding

14 18F-FDG PET/CT findings were validated by biopsy, histop

15 18F-FDG PET/CT has rapidly become a widely used imaging

16 18F-FDG PET/CT results were true-negative in 19 patients

17 18F-FDG PET/CT scans of gluteal and quadriceps muscle ar

18 18F-FDG PET/CT showed bilateral hypermetabolic adrenal m

19 18F-FDG PET/CT was true-positive in 4 and false-positive

20 18F-FDG uptake is more variable, with 65% of metabolical

21 18F-FDG uptake was particularly high in subjects with pe

22 18F-FDG uptake was quantified as Ki, calculated by 3-com

23 18F-FDG uptake was significantly higher in the carotid a

24 18F-FDG-PET-CT scans revealed almost complete inhibition

25 18F-FDG-PET/CT accuracy was determined in the subgroups

26 d 6 thoracic (thoracic aortic), who had >/=1 18F-FDG positron emission tomography/computed tomography

27 agreement of +/-0.21 (18F-NaF) and +/-0.13 (18F-FDG) for maximum tissue-to-background ratios.

28 ts (18F-NaF: 2.87+/-0.82 versus 1.55+/-0.17; 18F-FDG: 1.58+/-0.21 versus 1.30+/-0.13; both P<0.001).

29 er, retrospective cohort study including 234 18F-FDG PET examinations in 199 lung transplant recipien

30 grade 3, and 16 patients (10.7%) had grade 4 18F-FDG uptake for DSD.

31 Abnormal 18F-FDG uptake was assessed visually and by measuring th

32 The inclusion of abnormal 18F-FDG cardiac uptake as a major criterion at admission

33 formation, PET/CT detected sites of abnormal 18F-FDG uptake having an SUVmax of greater than 5.

34 residual lymphadenopathy, a lack of abnormal 18F-FDG uptake in these nodes also excludes viable tumor

35 Sites of abnormal 18F-FDG uptake with a maximum standardized uptake value

36 iated with high arterial metabolic activity (18F-FDG uptake).

37 In addition, 18F-FDG PET revealed clinically relevant incidental find

38 , femoral, and carotid arteries 90 min after 18F-FDG administration.

39 PET with the glucose analog 18F-FDG is increasingly being used to monitor the effect

40 and the PET signals of both 11C-acetate and 18F-FDG.

41 of 11 patients who had both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional si

42 racted from CT, 18F-FDG PET, and both CT and 18F-FDG PET.

43 dovascular infection on echocardiography and 18F-FDG-PET/CT, were free of relapse after IV-oral switc

44 nt accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting resi

45 he accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease after ne

46 PD-L1) and CTLA-4, followed by 68Ga-FAPI and 18F-FDG micro-PET/CT imaging to assess tumor responses.R

47 otor state underwent PET using 18F-FEOBV and 18F-FDG on two separated days.

48 s 0, 3, 7, 14, and 21) using 18F-FPPRGD2 and 18F-FDG.

49 on and computed tomography using 18F-NaF and 18F-FDG radiotracers.

50 We compared 18F-NaF and 18F-FDG uptake with histological characterization of the

51 their coronary calcium score and 18F-NaF and 18F-FDG uptake.

52 stenosis) were administered both 18F-NaF and 18F-FDG.

53 between inflammatory infiltrate patterns and 18F-FDG-PET/CT uptake were investigated in an explorator

54 A three-dimensional brain phantom and 18F-FDG patient studies are used to evaluate image quali

55 x computed by finite element simulations and 18F-FDG uptake were evaluated in a total of 68 examinati

56 Technetium-99m-ECD SPECT and 18F-FDG PET showed regional luxury perfusion at the left

57 BAT volume and 18F-FDG uptake were not associated with quantified ad li

58 ata and 0 or 1 blood sample for small-animal 18F-FDG PET studies.

59 y the glucose metabolic rate in small-animal 18F-FDG PET studies.

60 o determine the optimal measures of arterial 18F-FDG uptake for future studies.

61 Even though nonspecific tracers such as 18F-FDG visualize certain normal anatomic structures, th

62 cause it generally has lower iodine avidity, 18F-FDG PET has been suggested as a more accurate imagin

63 ass compared to those without detectable BAT 18F-FDG uptake.

64 Neither BAT volume, nor BAT 18F-FDG uptake after cold stimulation, are related to ap

65 apsed after meal consumption nor that of BAT 18F-FDG uptake x time elapsed after meal consumption had

66 BAT volume, BAT 18F-FDG uptake, and skeletal muscle 18F-FDG uptake were

67 Because 18F-FDG is also used in baseline staging PET/CT scans an

68 There was no significant correlation between 18F-FDG uptake and CD68 staining (r=-0.43; P=0.22).

69 vestigate whether correlations exist between 18F-FDG uptake of primary breast cancer lesions and pred

70 e improved by extending the interval between 18F-FDG administration and PET data acquisition.

71 Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized upt

72 In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its component

73 ed from 22 institutions underwent whole-body 18F-FDG PET, including dedicated PET of the brain, after

74 patients >18 y old, referred for whole-body 18F-FDG PET/CT for evaluation of known or suspected mali

75 ardium) were successfully extracted for both 18F-FDG and 1-11C-acetate in rats.

76 evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories.

77 Melanoma metastases were detected by 18F-FDG PET, 9-[4-(18)F-fluoro-3-(hydroxymethyl)butyl]gu

78 by immune cells and subsequent detection by 18F-FDG PET.

79 of cortical or subcortical hypometabolism by 18F-FDG PET is an unfavorable predictor.

80 ions in arterial inflammation as measured by 18F-FDG PET/CT were related to improvements in stress my

81 associated glucose metabolism as measured by 18F-FDG uptake of the primary breast cancer lesions.

82 nodes on the left side was detected only by 18F-FDG imaging.

83 negative, thyroglobulin-positive patients by 18F-FDG PET/CT may aid in the clinical management of sel

84 ng to diagnostic classifications provided by 18F-FDG PET at baseline and clinical diagnoses after a m

85 Risk stratification by 18F-FDG PET appears to be at least as predictive as the

86 best-fitting model to assess SMGU studied by 18F-FDG.

87 und effect on Patlak kinetics and calculated 18F-FDG uptake.

88 In addition, 15 cardiac 18F-FDG patients (having either pacing leads, defibrilla

89 blood markers, and fasting combined cardiac 18F-FDG PET/MRI imaging were obtained.

90 hout known cardiac disease underwent cardiac 18F-FDG-PET for assessment of arterial wall inflammation

91 ecific activity of the tracer (in this case, 18F-FDG), which are distorted because of the breathing m

92 entre observational cohort study we combined 18F-FDG and multi-tracer oxygen-15 PET to comprehensivel

93 In a prospective study, we compared 18F-FDG and L-methyl-11C-methionine (11C-methionine) PET

94 Coregistered 18F-FDG PET/CT can provide precise anatomic localization

95 Quantification of coronary 18F-FDG uptake was hampered by myocardial activity and w

96 ns should consider and insurers should cover 18F-FDG PET/CT when evaluating patients with FUO, partic

97 odules by use of features extracted from CT, 18F-FDG PET, and both CT and 18F-FDG PET.

98 were, first, to analyze standard and delayed 18F-FDG PET images visually and quantitatively to determ

99 None of the missed nodules demonstrated 18F-FDG uptake.

100 To establish the optimal time during 18F-FDG uptake for blood sampling when using an SUV, a P

101 hetized and were inside the tomograph during 18F-FDG uptake, whereas 6 animals were awake in their ho

102 healthy male volunteers underwent 2 dynamic 18F-FDG PET/CT scans with an interval of 24 h.

103 nsulin treatment, reflecting the rapid early 18F-FDG uptake.

104 ur objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory br

105 We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgki

106 de between animals given 124I-anti-CEA Fab', 18F-FDG, the same peptide radiolabeled with 111In and pr

107 d both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional sites of disease.

108 ell thyroid cancer who underwent their first 18F-FDG PET scan between May 1996 and February 2003 were

109 of defining and solving standard blood flow, 18F-FDG, and receptor models as well as models of a user

110 ons of BAT volume and 18F-fluordeoxyglucose (18F-FDG) uptake after a personalized cold exposure with

111 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel biomarkers of disease activ

112 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active plaque calcification and i

113 with 11C-acetate and 18F-fluorodeoxyglucose (18F-FDG) functionally visualizes the reactive astrocyte-

114 unknown origin, when 18F-fluorodeoxyglucose (18F-FDG) is not available.

115 Conversely, 18F-fluorodeoxyglucose (18F-FDG) PET signal was not different in Y. enterocoliti

116 erwent 68Ga-FAPI and 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging.

117 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of positron emission tomogr

118 erminal density, and 18F-fluorodeoxyglucose (18F-FDG) was performed in a cohort of people with Parkin

119 with fluorine 18-labeled fluorodeoxyglucose (18F-FDG) positron emission tomography combined with comp

120 In 4 patients, PET found focal 18F-FDG uptake in the brain suggestive of metastatic dis

121 For 18F-FDG, no correlation between covariance patterns and

122 ients for the input functions were 0.930 for 18F-FDG and 0.972 for 1-11C-acetate.

123 ients for the input functions were 0.973 for 18F-FDG and 0.965 for 1-11C-acetate.

124 rictive allograft syndrome as indication for 18F-FDG PET comprised relatively small groups (14 and 31

125 ses, unrelated to the primary indication for 18F-FDG PET, are found relatively often in this immunoco

126 least 1 lesion site of active metabolism for 18F-FDG or 11C-methionine, which could be used as an ind

127 1), with a more modest increase observed for 18F-FDG (r(2)=0.218, P<0.001).

128 Referral for 18F-FDG PET after lung transplantation mainly occurred t

129 Furthermore, 18F-FDG PET correctly classified as negative 3 patients

130 that image smearing can be reduced by gating 18F-FDG PET images in synchronization with the respirato

131 sured by [18F]-2-fluoro-d-2-deoxy-d-glucose (18F-FDG) PET/CT.

132 nt simulations and 18F-fluoro-deoxy-glucose (18F-FDG) positron emission tomography.

133 s missed in 1 patient who had only low-grade 18F-FDG uptake (SUVmax < 5).

134 arch has helped improve understanding of how 18F-FDG PET can best be applied.

135 ve protein (hsCRP) and leucopoietic imaging (18F-FDG PET uptake in spleen and bone marrow).

136 Large declines in 18F-FDG uptake tend to be seen in those with the longest

137 te, there were no significant differences in 18F-FDG uptake between patients and controls for all bra

138 days 3, 14, and 21, although an increase in 18F-FDG tumor uptake of treated mice, as compared with t

139 ed and found to reduce transmission noise in 18F-FDG cardiac emission images.

140 iteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET).

141 Increased 18F-FDG positron emission tomographic uptake in aortic a

142 Increased 18F-FDG uptake in DSD should not be confused with metast

143 Any increased 18F-FDG uptake was compared with the coregistered CT ima

144 8F-NaF uptake (>1.97), and 35% had increased 18F-FDG uptake (>1.63).

145 etrospectively for the presence of increased 18F-FDG uptake in the spine and for anatomic correlates.

146 strated >/=1 aneurysm wall area of increased 18F-FDG uptake.

147 In 2 patients, increased 18F-FDG uptake identified a second primary malignancy.

148 We also show that increased 18F-FDG uptake in non-metastatic nodes can be explained

149 brane potential is associated with increased 18F-FDG incorporation, glucose transport, and lactate pr

150 l events occurred in patients with increased 18F-FDG uptake on their last examination than in those w

151 chondrial membrane potential could influence 18F-FDG incorporation.

152 Intense 18F-FDG uptake in lesions is an indicator of a poor prog

153 /multi-focal or diffuse heterogenous intense 18F-FDG uptake on valvular and prosthetic material, peri

154 thetized animals, 6 received intraperitoneal 18F-FDG, whereas 4 received intravenous 18F-FDG, and all

155 all 6 awake animals received intraperitoneal 18F-FDG.

156 neal 18F-FDG, whereas 4 received intravenous 18F-FDG, and all 6 awake animals received intraperitonea

157 first-pass scan-and 3 sequential 15-min late 18F-FDG uptake scans.

158 One hour later, 18F-FDG was injected, followed by a 3-h dynamic PET scan

159 have developed a new technique to gate lung 18F-FDG PET images in synchronization with the respirato

160 x constant Ki as the method to quantify lung 18F-FDG uptake, we also showed that Ki correlated positi

161 In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly a

162 ) after the intravenous injection of 2.5 MBq 18F-FDG per kilogram of body weight.

163 a maximum regional DSD score of 3, the mean 18F-FDG uptake for that spinal level was 1.4 +/- 1.5, wh

164 lymph node of TRL-positive patients misleads 18F-FDG-PET/CT for detecting nodal metastasis.

165 e demonstrate that pretreatment TRL misleads 18F-FDG-PET/CT during lymph node staging in gynecologica

166 ume, BAT 18F-FDG uptake, and skeletal muscle 18F-FDG uptake were assessed by means of static 18F-FDG

167 died radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

168 There were 24 positive and 20 negative 18F-FDG PET scans with 1 false-positive and 1 false-nega

169 ctive study may be necessary before negative 18F-FDG PET/CT may become the only, or at least most-dec

170 Only 1 patient with negative 18F-FDG PET had positive RIS.

171 native to dynamic imaging in determining net 18F-FDG uptake during ALI.

172 In patients with neurofibromatosis, 18F-FDG-PET demonstrated its application to detect and m

173 Finally, normal 18F-FDG PET/CT excluded residual disease at the primary

174 In patients with HNSCC, normal 18F-FDG PET/CT after chemoradiotherapy has a high NPV an

175 d hepatocellular carcinoma (HCC) that is not 18F-FDG-avid.

176 Accuracy of 18F-FDG PET for other indications is less clear, given s

177 lysis was performed to determine accuracy of 18F-FDG PET in each group.

178 The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient grou

179 ll sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 68.4%, 82.4%, and 73.8%, respectivel

180 tion may affect the quantitative analysis of 18F-FDG PET scans and summarizes the results of recent s

181 No significant decrease of 18F-FDG uptake was found between the treated and the con

182 h was followed by a 370-MBq (10 mCi) dose of 18F-FDG.

183 the limitations of incomplete extraction of 18F-FDG compared with 15O-water.

184 tially, PET images were examined and foci of 18F-FDG uptake in the spine were graded on a 0-4 scale b

185 The increase of 18F-FDG on day 7 was related to the inflammatory respons

186 graded on a 0-4 scale based on intensity of 18F-FDG uptake (0 = definitely normal, 1 = probably norm

187 fter intravenous injection of 400-610 MBq of 18F-FDG using a combined PET/CT scanner.

188 e intravenous injection of 383 +/- 15 MBq of 18F-FDG.

189 ravenous injection of 7.77 MBq (0.21 mCi) of 18F-FDG per kilogram of body weight, PET emission scans

190 esions (26%) had no detectable metabolism of 18F-FDG or 11C-methionine.

191 not been assessed, and the optimal method of 18F-FDG quantification is still debated.

192 ducibility measures and compare 2 methods of 18F-FDG uptake measurement.

193 tosis (TRL) on the diagnostic performance of 18F-FDG-PET/CT in detecting pelvic and paraaortic lymph

194 due to breathing and improve quantitation of 18F-FDG uptake in lung lesions.

195 lated numbers needed to treat for receipt of 18F-FDG-PET/CT were 7-9 to change antimicrobial therapy,

196 ished independently, based on the results of 18F-FDG SPECT as well as PET.

197 iterature, we evaluated the emerging role of 18F-FDG PET in staging, response assessment, risk strati

198 tlined, this article will review the role of 18F-FDG PET in the management of patients with lymphoma.

199 g relapse-free cure, and the overall role of 18F-FDG-PET-CT as a tool for early-phase tuberculosis cl

200 Four sequential scans of 18F-FDG uptake were acquired, consisting of an early 2-m

201 The sensitivities of 18F-FDG PET and 11C-methionine PET were 48% (167/348 les

202 The sensitivities of 18F-FDG PET/CT at serum thyroglobulin levels of less tha

203 Sensitivity of 18F-FDG PET for malignancy was 91.4% (95% confidence int

204 C-CFN (2.42 +/- 1.17) but lower than that of 18F-FDG (7.74 +/- 0.53).

205 sue contrast is generally lower than that of 18F-FDG in most cancers outside the brain.

206 thods of quantifying the pulmonary uptake of 18F-FDG could be as powerful as calculating Ki.

207 tudy was to determine if the early uptake of 18F-FDG could be used to measure regional blood flow in

208 ormant sites followed by increased uptake of 18F-FDG during progression of disease.

209 esults suggest that the first-pass uptake of 18F-FDG may provide an estimate of perfusion in a tumor

210 lood flow estimated from the early uptake of 18F-FDG was linearly correlated with 15O-measured blood

211 of guidelines and algorithms for the use of 18F-FDG PET/CT in the evaluation and management of head

212 Use of 18F-FDG-PET/CT at the initial presentation of patients w

213 , there is limited evidence regarding use of 18F-FDG-PET/CT for the diagnosis of native valve endocar

214 s who present with suspected NVE, the use of 18F-FDG-PET/CT is less accurate and could only be consid

215 We investigated the clinical utility of 18F-FDG PET/CT in this setting.

216 diagnostic accuracy and prognostic value of 18F-FDG PET in this disease.

217 d positive and negative predictive values of 18F-FDG-PET/CT focal uptake were 93%, 90%, 89%, and 94%,

218 eural network activity (SNA) was assessed on 18F-FDG PET as amygdala relative to ventromedial prefron

219 alone (F = 0.097, P > 0.05) had no effect on 18F-FDG uptake but ER state alone had an effect (F = 9.1

220 R being together had no additional effect on 18F-FDG uptake.

221 tionship between the severity of findings on 18F-FDG PET and the severity of degenerative spinal dise

222 Thirty patients had positive findings on 18F-FDG PET/CT; 26 were true-positive and 4 were false-p

223 oor contrast resolution and were not seen on 18F-FDG PET because of higher background uptake relative

224 ion in the TBR of MDS of the index vessel on 18F-FDG PET/CT correlated with improvement in the stress

225 ancer confirms the utility of the first-pass 18F-FDG blood flow analysis in tumor diagnosis.

226 In patients, 18F-FDG scans also were performed.

227 Dual time point 18F-FDG PET results in a very high sensitivity and speci

228 G PET scanning with those of dual time point 18F-FDG PET scanning.

229 T4-to-GLUT3 substrate switching, positioning 18F-FDG PET as a dynamic biomarker for monitoring HPC ag

230 estigations, we show that the false-positive 18F-FDG-PET/CT result for detecting nodal metastasis can

231 Ten patients with positive 18F-FDG PET had negative RIS.

232 MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemic

233 a follow-up of up to 5.9 y after prospective 18F-FDG PET imaging.

234 and maximum TBR measurements for quantifying 18F-FDG uptake are equally reproducible.

235 Quantitatively, 18F-FDG positron emission tomographic uptake correlated

236 Indication for PET referral, 18F-FDG PET diagnosis/findings and final clinical diagno

237 Semiquantitative analysis of regional 18F-FDG uptake was performed in both cortical and subcor

238 In 3 of 6 patients with positive RIS, 18F-FDG PET revealed additional sites of metastatic dise

239 In this specific setting, 18F-FDG PET has a high diagnostic yield.

240 determined the prevalence of abnormal spinal 18F-FDG uptake and assessed the relationship between the

241 compares the diagnostic accuracy of standard 18F-FDG PET scanning with those of dual time point 18F-F

242 of 7 patients underwent an additional static 18F-FDG PET scan for clinical indications.

243 -FDG uptake were assessed by means of static 18F-FDG positron-emission tomography and computed tomogr

244 T identified significantly more lesions than 18F-FDG PET (P < 0.01).

245 The 18F-FDG tumor extraction fraction relative to 15O-water

246 the areas under the curves (AUCs) and in the 18F-FDG influx constant Ki in 3 types of tissue.

247 anied by an increase in the intensity in the 18F-FDG signal per voxel.

248 excellent short-term reproducibility of the 18F-FDG signal, with intraclass correlation coefficients

249 lesions with high sensitivity because of the 18F-FDG uptake in glycolytically active cells that may r

250 al protocol in which animals can receive the 18F-FDG tracer injection intraperitoneally, away from th

251 Consequently, 18F-FPPRGD2 PET is superior to 18F-FDG PET in monitoring early response to treatment, f

252 al skeleton MRI have been proven superior to 18F-FDG PET/computed tomography.

253 ron emission tomography/computed tomography (18F-FDG PET/CT) imaging of the aorta and carotid arterie

254 ron emission tomography-computed tomography (18F-FDG-PET/CT) can be influenced by the increased glyco

255 ron emission tomography/computed tomography (18F-FDG-PET/CT) has emerged as a useful diagnostic tool

256 rodeoxyglucose positron emission tomography (18F-FDG PET) imaging in the follow-up of patients with d

257 rodeoxyglucose positron emission tomography (18F-FDG-PET) is being used with increased frequency in t

258 Changes in tumor 18F-FDG uptake correlate significantly with histopatholo

259 A typical 18F-FDG clinical brain study requires only 2 mCi to achi

260 h Hurthle cell thyroid cancer should undergo 18F-FDG PET as part of their initial postoperative stagi

261 0Y-ibritumomab tiuxetan (n=10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12

262 with newly diagnosed breast cancer underwent 18F-FDG PET (5.2 MBq/kg of body weight).

263 cal suspicion of recurrent disease underwent 18F-FDG PET/CT.

264 nts with lymph node metastases who underwent 18F-FDG PET/CT > or = 8 wk after the end of therapy were

265 -71 y) and newly diagnosed IBC who underwent 18F-FDG PET/CT at diagnosis were retrospectively reviewe

266 formed of 37 patients with CLL who underwent 18F-FDG PET/CT at our institution between March 2003 and

267 inflammation and burden were assessed using 18F-FDG PET (as maximal target-to-background ratio, TBR

268 aged 20 patients with vascular disease using 18F-FDG PET twice, 14 d apart, and used these data to as

269 e mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 with 11C-MeAIB, compared with 33.7

270 nding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 with 11C-MeAIB, and 125.4 mm3 by hist

271 histology-derived volumes was obtained using 18F-FDG, MAP3D reconstruction, and fixed thresholding of

272 udy was to evaluate the feasibility of using 18F-FDG and PET for the detection of infection associate

273 PET using 18F-FDG has been shown to effectively detect various typ

274 of PET in myocardial viability studies using 18F-FDG.

275 icant correlation was noted between valvular 18F-FDG uptake and change in calcium score (r=-0.11; P=0

276 Vessel 18F-FDG uptake was measured as both the mean and maximum

277 toparietal cortical brain perfusion, whereas 18F-FDG cerebral uptake was normal.

278 With 18F-FDG, PET/CT is rapidly becoming the key investigativ

279 nsisted of a 60-min dynamic acquisition with 18F-FDG (18.5-29.6 MBq).

280 major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demon

281 oving targeting specificity as compared with 18F-FDG.

282 PET/CT with 18F-FDG is increasingly being used for staging, restagin

283 Response evaluation with 18F-FDG PET-CT revealed a relative decrease of maximum s

284 Dynamic PET imaging with 18F-FDG (7.7+/-0.9 MBq) was conducted.

285 6 BALB/c mice underwent dynamic imaging with 18F-FDG (n = 6) and 1-11C-acetate (n = 6).

286 Whole-body PET imaging with 18F-FDG has been used successfully to stage colorectal c

287 Imaging with 18F-FDG PET is increasingly accepted as a valuable tool

288 Atherosclerosis imaging with 18F-FDG PET is useful for tracking inflammation within p

289 lished indication for metabolic imaging with 18F-FDG.

290 delineation of gliomas from gray matter with 18F-FDG PET could be improved by extending the interval

291 of the incorporation of regional nodes with 18F-FDG avidity that were previously judged to be uninvo

292 ng disease-specific metabolism patterns with 18F-FDG PET compared with that of clinical diagnosis.

293 PET with 18F-FDG has gained a role in the staging and follow-up o

294 eted a trial evaluating the role of PET with 18F-FDG in patients with documented or suspected non-sma

295 PET with 18F-FDG may be useful for quantifying neutrophilic activ

296 too small to be characterized reliably with 18F-FDG PET.

297 arotid artery cannulations were studied with 18F-FDG small-animal PET accompanied by serial arterial

298 pretargeted animals less ambiguous than with 18F-FDG.

299 Tumor visualization with 18F-FDG at approximately 1.5 h was also good but showed

300 Over the past 20 years 18F-FDG has established itself as a valuable imaging age